e Of the nonfatal strokes on aspirin clopidogrel therapy, an estimated were ischemic, and ve were hemorrhagic. f Of the nonfatal strokes on VKA therapy, an estimated were ischemic, and were hemorrhagic. g We estimated the annual rates of nonfatal stroke (ischemic and hemorrhagic) on aspirin clopidogrel by extrapolating from observed annual rates of ischemic stroke (fatal nonfatal), strati ed by CHADS score, in the aspirin arms of six historical RCTs in patients with AF (Gage et al ). Assumptions underlying these estimates are detailed in section of this article. h The published report did not provide the number of major extracranial bleeds that were fatal and nonfatal; therefore, we imputed values for the number of fatal and nonfatal major extracranial bleeds to estimate the relative risk for nonfatal major extracranial bleeds. Assumptions underlying these estimates are detailed in section of this article. i The CI does not exclude appreciable harm or bene t with VKA therapy. j Rate of nonfatal major extracranial bleeding on aspirin clopidogrel is extrapolated from rates observed in observational cohorts of patients receiving VKA therapy (median, and estimated relative risks of nonfatal major extracranial bleeding associated with VKA therapy compared with no therapy (RR, aspirin compared with no therapy (RR, and aspirin clopidogrel compared with aspirin (RR, 1.50). k Estimate is derived from rate of systemic embolism on aspirin per patient-y) reported in the IPD meta-analysis by van Walraven et al and estimated relative risk of CI, for systemic embolism with combination aspirin clopidogrel therapy vs aspirin observed in ACTIVE A ( Table ). 